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Reply to Townes-Anderson: RPE65 Gene Therapy Does Not Alter the
Natural History of Retinal Degeneration
Abstract
We appreciate the interest shown by TownesAnderson in our article examining the natural history of retinal
degeneration in Leber congenital amaurosis caused by retinal pigment epithelium-specific protein 65kDa
(RPE65) mutations and evaluating the consequences of gene augmentation therapy. Townes-Anderson’s
remarks focused on the final phrase of the last sentence of the Discussion of our article. In the full sentence, we
suggested that in the future, agents to reduce cell death could be delivered in combination with a more
advanced version of the gene augmentation therapy that reaches not only remaining rods and extrafoveal
cones but also foveal cone photoreceptors.
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LETTER
Reply to Townes-Anderson: RPE65 gene
therapy does not alter the natural history
of retinal degeneration
We appreciate the interest shown by Townes-
Anderson (1) in our article examining the
natural history of retinal degeneration in
Leber congenital amaurosis caused by retinal
pigment epithelium-speciﬁc protein 65kDa
(RPE65) mutations and evaluating the conse-
quences of gene augmentation therapy (2).
Townes-Anderson’s remarks focused on the
ﬁnal phrase of the last sentence of the Dis-
cussion of our article. In the full sentence,
we suggested that in the future, agents to
reduce cell death could be delivered in com-
bination with a more advanced version of
the gene augmentation therapy that reaches
not only remaining rods and extrafoveal
cones but also foveal cone photoreceptors.
Towne-Anderson made the constructive
point that consideration should be given in
future versions of human RPE65 gene ther-
apy to a speciﬁc rod photoreceptor cell-
death pathway (3). We are familiar with
the Townes-Anderson hypothesis involving
G-protein activation by mislocalized opsin,
and we have recently cited this hypothesis
as potentially relevant for our work dem-
onstrating successful arrest of retinal de-
generation by gene augmentation therapy
in the RPGR form of X-linked retinitis pig-
mentosa (4). However, disease mechanisms
in the retinoid deﬁciency caused by RPE65
mutations and in the ciliopathy caused by
RPGR mutations are likely to be different.
It is important to note that chromophore in
RPE65-mutant retinas is nearly undetect-
able and thus the majority of mislocalized
opsin molecules are not likely to be bound
to chromophore. The protection from bright
light in Rpe65-deﬁcient mice—as opposed to
exacerbation of degeneration—argues against
a primary signaling pathway involving photo-
activation of mislocalized isorhodopsin or
rhodopsin. Alternatively, it could be argued
that mislocalized free opsin is involved. In-
deed, there is evidence that constitutive acti-
vation of G protein by free opsin contrib-
utes to cell death in Rpe65-deﬁciency, but
whether signaling originates from free opsin
correctly localized to rod outer segments or
mislocalized to the inner segments remains
unknown.
In patients who received gene augmenta-
tion therapy, there is a likely increase in 11-
cis-retinal chromophore availability to rods
and extrafoveal cones (5). According to the
Townes-Anderson hypothesis, the increase
in chromophore produced by gene therapy
together with ambient light should have
resulted in activation of mislocalized rho-
dopsin (1). Such signaling would be predicted
to accelerate the rate of cell loss beyond that
measured in the natural history of disease.
However, the rate of degeneration within
the retinal regions that received gene ther-
apy was not faster than the natural history
(2), and thus did not support the Townes-
Anderson hypothesis.
In summary, we ﬁnd no speciﬁc sup-
port in our data for the hypothesis ad-
vanced by Townes-Anderson; however,
we wholeheartedly agree with the senti-
ment that we should proceed cautiously
to improve the outcomes of retinal gene
augmentation therapy including RPE65
gene therapy.
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